Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: TRIO Clear all
Withdrawn Phase 1 Interventional

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

NCT04073160
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tremelimumab, Durvalumab, Bladder radiation, Intravesicular Therapy
Drug · Radiation
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jul 21, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Trio Laser Module for Hair Removal Treatment

NCT04599751
View directory record Official record
Conditions
Hair Removal Treatment
Interventions
Hair removal treatment
Device
Lead sponsor
Alma Lasers
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Hollywood, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Jul 21, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

NCT01728363
View directory record Official record
Conditions
Systemic Infection
Interventions
Antibiotic
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
14 Days to 32 Weeks
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 21, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time-Restricted Feeding

NCT04884659
View directory record Official record
Conditions
Obesity, Inflammatory Markers, Glycemic Variation, Time Restricted Feeding, Ketosis
Interventions
Time restricted feeding arm, usual feeding pattern arm
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 21, 2026, 10:12 PM EDT
Active, not recruiting Phase 2 Interventional

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

NCT03672773
View directory record Official record
Conditions
Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma
Interventions
Talazoparib, Temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
6
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 21, 2026, 10:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

NCT03830918
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Biological · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 21, 2026, 10:12 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms

NCT01444859
View directory record Official record
Conditions
Recurrent Gastrointestinal Symptoms
Interventions
Trenev Trio®/Healthy Trinity®, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • West Lawn, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Jul 21, 2026, 10:12 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

NCT01268618
View directory record Official record
Conditions
IBS-D and Functional Dyspepsia
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Duluth, Georgia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Jul 21, 2026, 10:12 PM EDT
Recruiting Phase 1 Interventional

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

NCT04470024
View directory record Official record
Conditions
Cancer of the Head and Neck
Interventions
INCAGN01876, INCMGA00012, DPV-001
Drug · Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 10:12 PM EDT
Completed Not applicable Interventional

RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor

NCT05540626
View directory record Official record
Conditions
Essential Tremor
Interventions
Cala Trio
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jul 21, 2026, 10:12 PM EDT
Recruiting No phase listed Observational

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

NCT01238250
View directory record Official record
Conditions
16P11.2 Deletion Syndrome, 16p11.2 Duplications, 1Q21.1 Deletion, 1Q21.1 Microduplication Syndrome (Disorder), ACTL6B, ADNP, AHDC1, ANK2, ANKRD11, ARID1B, ASH1L, BCL11A, CHAMP1, CHD2, CHD8, CSNK2A1, CTBP1, CTNNB1 Gene Mutation, CUL3, DDX3X, DNMT3A, DSCAM, DYRK1A, FOXP1, GRIN2A, GRIN2B, HIVEP2-Related Intellectual Disability, HNRNPH2, KATNAL2, KDM5B, KDM6B, KMT2C Gene Mutation, KMT2E, KMT5B, MBD5, MED13L, PACS1, PPP2R5D-Related Intellectual Disability, PTCHD1, REST, SCN2A Encephalopathy, SETBP1 Gene Mutation, SETD5, SMARCA4 Gene Mutation, SMARCC2, STXBP1 Encephalopathy With Epilepsy, SYNGAP1-Related Intellectual Disability, TBR1, ARHGEF9, HNRNPU, PPP3CA, PPP2R1A, SLC6A1, 2p16.3 Deletions, 5q35 Deletions, 5q35 Duplications, 7q11.23 Duplications, 15Q13.3 Deletion Syndrome, 16p11.2 Triplications, 16P12.2 Microdeletion, 16P13.11 Microdeletion Syndrome (Disorder), 17Q12 Microdeletion Syndrome (Disorder), 17Q12 Duplication Syndrome, 17Q21.31 Deletion Syndrome, 17q21.3 Duplications, ACTB, ADSL, AFF2, ALDH5A1, ANK3, ARX, ATRX Gene Mutation, AUTS2 Syndrome, BCKDK, BRSK2, CACNA1C, CAPRIN1, CASK, CASZ1, CHD3, CIC, CNOT3, CREBBP Gene Mutation, CSDE1, CTCF, DEAF1, DHCR7, DLG4, EBF3, EHMT1, EP300 Gene Mutation, GIGYF1, GRIN1, GRIN2D, IQSEC2-Related Syndromic Intellectual Disability, IRF2BPL, KANSL1, KCNB1, KDM3B, NEXMIF, KMT2A, MBOAT7, MEIS2, MYT1L, NAA15, NBEA, NCKAP1, NIPBL, NLGN2, NLGN3, NLGN4X, NR4A2, NRXN1, NRXN2, NSD1 Gene Mutation, PHF21A, PHF3, PHIP, POMGNT1, PSMD12, RELN, RERE, RFX3, RIMS1, RORB, SCN1A, SETD2 Gene Mutation, SHANK2, SIN3A, SLC9A6, SON, SOX5, SPAST, SRCAP, TAOK1, TANC2, TCF20, TLK2, TRIO, TRIP12, UPF3B, USP9X, VPS13B, WAC, WDFY3, ZBTB20, ZNF292, ZNF462, 2Q37 Deletion Syndrome, 9q34 Duplications, 15q15 Deletions, 15Q24 Deletion, NR3C2, SYNCRIP, 2q34 Duplication, 2q37.3 Deletion, 6q16 Deletion, 15q11.2 BP1-BP2 Deletion, 16p13.3 Deletion, 17Q11.2 Microduplication Syndrome (Disorder), 17p13.3, Xq28 Duplication, CLCN4, CSNK2B, DYNC1H1, EIF3F, GNB1, MED13, MEF2C, RALGAPB, SCN1B, YY1, Xp11.22 Duplication, PACS2, MAOA, MAOB, HNRNPC, HNRNPD, HNRNPK, HNRNPR, HNRNPUL2, 5P Deletion Syndrome, TCF7L2 Gene Mutation, HECW2
Interventions
Not listed
Lead sponsor
Simons Searchlight
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2050
U.S. locations
2
States / cities
Boston, Massachusetts • Lewisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 21, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands

NCT05480215
View directory record Official record
Conditions
Essential Tremor, Parkinson Disease
Interventions
Cala Device
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 21, 2026, 10:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kosmos Trio and Ejection Fraction Pivotal Study

NCT06027164
View directory record Official record
Conditions
Cardiac Disease
Interventions
Portable Ultrasound System
Device
Lead sponsor
EchoNous Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jul 21, 2026, 10:12 PM EDT